Aug 08, 2019 / 11:00PM GMT
Operator
Welcome to Amarin Corporation's conference call to provide a corporate update following today's announcement regarding a planned public advisory committee meeting related to the REDUCE-IT supplemental new drug application pending with FDA. This conference call is being recorded today, August 8, 2019.
I will now turn the conference over to Elisabeth Schwartz, Senior Director of Investor Relations of Amarin.
Elisabeth Schwartz - Amarin Corporation plc - Senior Director of IR
Good evening. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements include, but are not limited to our current views on FDA's plan to hold a REDUCE-IT advisory committee meeting and related subject matter and timing, FDA's review of the REDUCE-IT sNDA and related timing, our expectations on the effect of REDUCE-IT on Vascepa sales and patient care, our plans for sales force and commercial expansion and financial
Amarin Corporation plc - Special Call Transcript
Aug 09, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers